
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Los Angeles - Cutaneous atrophy, the bane of topical corticosteroid treatment, may have met its match in a thyroid hormone analogue, according to Jan Faergemann, M.D., Ph.D.






